Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Pío del Río Hortega (8)

2024

  1. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853

2022

  1. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2017

  1. Tuberculosis, one more consideration in the differential diagnosis of a pancreatic mass

    Gastroenterologia y Hepatologia, Vol. 40, Núm. 9, pp. 619-621

2015

  1. Early detection of high oxidative activity in patients with adenomatous intestinal polyps and colorectal adenocarcinoma: Myeloperoxidase and oxidized low-density lipoprotein in serum as new markers of oxidative stress in colorectal cancer

    Laboratory Medicine, Vol. 46, Núm. 2, pp. 123-135

  2. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments

    Alimentary Pharmacology and Therapeutics, Vol. 41, Núm. 8, pp. 768-775

2009

  1. High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD

    Mediators of Inflammation, Vol. 2009